Daihan Pharmaceutical Co.,Ltd.
023910.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$152B
Close$
Share Statistics
| Market cap | $152.00 Billion |
|---|---|
| Enterprise Value | $95.07 Billion |
| Dividend Yield | $900.00 (3.48%) |
| Earnings per Share | $4701 |
| Beta | 0.17 |
| Outstanding Shares | 5,880,000 |
Return
| Return on Equity | 8.94% |
|---|---|
| Return on Assets | 7.66% |
| Return on Invested Capital | 10.12% |
Valuation & Multiples
| P/E Ratio | 5.52 |
|---|---|
| PEG | 62.29 |
| Price to Sales | 0.7 |
| Price to Book Ratio | 0.5 |
| Enterprise Value to Revenue | 0.44 |
| Enterprise Value to EBIT | 3 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$53.10 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$59.10 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Daihan Pharmaceutical Co.,Ltd.
675 employees
CEO: Sungyoung Lee Operating from South Korea, Daihan Pharmaceutical Co.,Ltd. focuses on the development, manufacturing, and distribution of therapeutic medications. The company's diverse product portfolio features physician-prescribed drugs, over-the-coun...